Skip to main content
SP5007,678.50+0.02%DOW53,470.11-0.20%NASDAQ26,113.23-0.15%BTC$78,072.00-1.63%ETH$2,449.13-1.11%GOLD$4,654.40-0.85%OIL$82.44+0.10%
Smart Investors Daily
Sign InSign Up Free
TL

OTC · TLIS

Talis Biomedical Corporation

Healthcare · Medical - Devices

$2.84

Up+$0.00 (+0.00%)

Updated Aug 26, 2026, 3:48 PM

SID Score

4.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
2.92M
P/E ratio
-0.05
Dividend yield
0.00%
52-week range
$1.04 – $2.84
Volume
59.31K
Avg. volume
282

Price performance

TLIS price history

1M range · 0 trading sessions · Daily adjusted prices

TLIS does not have enough price history for the selected period.

Data unavailable

Market data is busy. Please try again shortly.

Latest TLIS news

The latest Smart Investors Daily articles mentioning TLIS.

Stock researchCompany · Overview

TLIS research

Overview

Company profile and research snapshot.

Company profile

TALIS BIOMEDICAL CORP

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
—
Implied upside
—
Analysts
—
TLIS recent ratings
DateFirmRatingTarget
Aug 16, 2023BTIGSell—
Mar 18, 2022BTIGSell—
Mar 16, 2022B of A SecuritiesUnderperform—
Jan 7, 2022B of A SecuritiesUnderperform—
Sep 27, 2021JP MorganUnderweight—
Open full forecast

News briefing

No generated briefing is available yet.

Benzinga · Aug 16, 2023

BTIG Maintains Sell Rating for Talis Biomedical: Here's What You Need To Know

BTIG has decided to maintain its Sell rating of Talis Biomedical (NASDAQ:TLIS) and raise its price target from $0.35 to $5.00. Shares of Talis Biomedical are trading down 4.35% over the last 24 hours, at $6.81 per share. A move to $5.00 would account for a 26.58% decrease from the current share price. About Talis Biomedical Talis Biomedical Corp is engaged in developing and commercializing products designed to enable molecular testing for infectious diseases and other conditions at the point-of-care. Its Talis One System is a molecular diagnostic platform developed to enable ...Full story available on Benzinga.com

GlobeNewswire Inc. · Aug 3, 2023

Talis Biomedical to Report Second Quarter 2023 Financial Results and Provide a Business Update on August 10, 2023

REDWOOD CITY, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will report second quarter 2023 financial results and provide a business update on Thursday, August 10, 2023, after market close. Company management will host a corresponding conference call beginning at 1:30 p.m. Pacific Time (4:30 p.m. Eastern Time).

GlobeNewswire Inc. · Jul 5, 2023

Talis Biomedical Announces 1-for-15 Reverse Stock Split

REDWOOD CITY, Calif., July 05, 2023 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a diagnostic company dedicated to advancing health equity and outcomes through the delivery of accurate infectious disease testing in the moment of need, at the point of care, today announced that it will effect a 1-for-15 reverse stock split of the Company’s issued and outstanding common stock, par value $0.0001 per share (the “Reverse Stock Split”), effective at 5:00 p.m. Eastern time on July 5, 2023 (the “Effective Time”). The Company’s common stock will begin trading on a reverse stock split adjusted basis on The Nasdaq Capital Market at market open on July 6, 2023.

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By